Mental Health

Although GLP-1 receptor agonists have shown promise in promoting weight loss, they are prescription medications and should be used under the guidance of health care professionals.

Although findings indicate a relationship between vitamin D and mood disorders, further research is needed to clarify efficacy of specific vitamin D levels, as well as supplement dose and form.

SSRI treatment for postnatal depression brought long-term benefits for mothers and their offspring in the following years after childbirth, study findings showed.

When children got less than the recommended 9 hours of sleep or took more than 30 minutes to fall asleep, there was a strong link to impulsive behaviors later in life.

KET01 could successfully treat treatment-resistant depression while limiting adverse effects in the home environment, according to the study.

Following an increase in government seizures of ayahuasca, an Indigenous religious organization requested government records that led to these seizures. The DEA responded by sending a single report condemning use of the drug.

Researchers sought to find a remedy for the development of treatment-resistant depression in patients whose antidepressant treatment has fluctuated in efficacy.

Although the rate of people with probable insomnia who discussed their sleep habits with a physician was relatively high, the number of people who went on to seek actual treatment was low.

The daily oral formulation of ketamine, KET01, has the potential to greatly improve the standard treatment practices for treatment-resistant depression, according to investigators.

Jennifer Chesak, author of The Psilocybin Handbook for Women, discusses how estrogen can affect binding at the serotonin receptor sites, causing psilocybin to impact women’s bodies differently.

The study implemented a novel workflow for ambulatory care pharmacists to execute pharmacist-administered depression screenings.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

However, the FDA said an application for zuranolone to treat major depressive disorder did not provide substantial evidence of efficacy.

The risk of death by suicide in soldiers was both directly and indirectly related to traumatic brain injury through confounding mental health diagnoses.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.

Generic ketamine could cost as little as $5, which is significantly lower than the $800 per dose for the currently available S-ketamine nasal spray.

Further research and regulatory changes are needed, but psychedelic medicines may be able to treat or even cure mental illness in the future.

The use of psilocybin and psychedelic therapy can be a helpful tool for individuals with AUD and could have a positive outcome that can result in self compassion.

The benefits of the survey can stretch beyond assessing the parental acceptability of mental health screenings in children and can suggest areas of optimization in providing these screenings more widely and effectively in the future.

Evidence shows vitamin D deficiency is linked to abnormal dopamine signaling disorders in neurodevelopment, including schizophrenia.

Employees who did frequently use AI systems were more than likely to offer help to fellow employees, though it could have been a response to their loneliness.

Several workplace risk factors, including safety concerns going unaddressed, predicted suicidal thoughts.

Depression can affect the trajectory of treatment and associated outcomes.

Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

The estimated cost burden of schizophrenia is more than $150 billion, consisting of direct treatment cost and lost productivity.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.